Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003202 · ClinicalTrials.gov registry record · Phase 1

Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

A Phase 1 study, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT00003202: Completed Phase 1 study, sponsored by Wake Forest University Health Sciences.

NCT00003202 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003202, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to compare the effectiveness of gemcitabine with radiation therapy alone or following two-drug combination chemotherapy in treating patients with stage III non-small cell lung cancer.

Interventions

  • DRUG cisplatin
  • RADIATION radiation therapy
  • DRUG gemcitabine hydrochloride

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 1998-01
Est. Completion 2006-07
Phase Phase 1
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT00003202 record still lists

NCT00003202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.

NCT00003202 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003202 about?

NCT00003202 is a clinical study titled "Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to compare the ...

What is the current status of trial NCT00003202?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 1998-01. Estimated completion is 2006-07.

What interventions are being tested in trial NCT00003202?

The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00003202?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00003202's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003202, the US trial registry maintained by the National Library of Medicine. NCT00003202 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.